Aphria quarterly revenue misses estimates as COVID-19 hits drug distribution
Adds segment revenue, estimates, shares, background
Oct 15 (Reuters) - Canadian pot producer Aphria Inc APHA.TO, APHA.O on Thursday missed estimates for quarterly revenue as reduced in-person visits to physicians and pharmacies due to COVID-19 curbs in Germany hit its distribution business, which accounts for half of total sales.
Aphria's first-quarter distribution revenue fell to C$82.2 million ($62.20 million) from C$99.1 million in the previous quarter and C$95.3 million from a year earlier.
The company posted net revenue of C$145.7 million in the quarter, missing Street estimates of C$159.7 million, according to IBES data from Refinitiv.
U.S.-listed shares of the company fell 10% in premarket trading, dragging other cannabis stocks with them.
The spread of the COVID-19 pandemic led to countries and states closing borders, disrupting supply chains with companies holding off new product launches and some even shutting stores.
Ontario-based Aphria also posted a net loss of C$5.1 million, or 2 Canadian cents per share, in the three months ended Aug. 31, compared with a net income of C$16.4 million or 7 Canadian cents per share, a year earlier.
The loss, however, was smaller than analysts' average estimate of a loss of 4 Canadian cents.
($1 = 1.3216 Canadian dollars)
(Reporting by Shradha Singh in Bengaluru; Editing by Ramakrishnan M.)
((Shradha.Singh@thomsonreuters.com; within U.S. +1 646 223 8780 Ext: 2804, outside U.S. +91 80 6182 2630;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.